Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment

被引:11
作者
Chen, Jialiang [1 ]
Xue, Dongying [3 ]
Gao, Fangyuan [1 ]
Tao, Le [3 ]
Li, Yuxin [1 ]
Zhang, Qun [2 ]
Wang, Rui [1 ]
Sun, Le [2 ]
Yang, Xue [1 ]
Liu, Yao [1 ]
Zhu, Bingbing [2 ]
Niu, Shuaishuai [1 ]
Wang, Xianbo [1 ]
机构
[1] Capital Med Univ, Beijing Ditan Hosp, Ctr Integrat Med, Beijing 100015, Peoples R China
[2] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Gastroenterol, Beijing, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Infect Dis, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
biochemical response; factors; primary biliary cholangitis; score model; ursodeoxycholic acid; LONG-TERM PROGNOSIS; OBETICHOLIC ACID; HEPATOCELLULAR-CARCINOMA; CIRRHOSIS; BILIRUBIN; AMINOTRANSFERASE; AUTOANTIBODIES; MANAGEMENT; DIAGNOSIS; FIBROSIS;
D O I
10.1097/MEG.0000000000001186
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims The biochemical response after ursodeoxycholic acid (UDCA) treatment contributes toward predicting the prognosis for primary biliary cholangitis (PBC) patients. This study aimed to establish a score model that can be used for predicting the biochemical response. Patients and methods A total of 218 patients in the derivation group and 66 patients in the verification group were enrolled. Response endpoints were based on the Barcelona criteria combined with the Paris I criteria. We determined independent factors of the biochemical response by univariate and multivariate analyses. Then, we established a predictive score model on the basis of regression coefficients after adjusted multivariate analyses. Results The median follow-up duration in the derivation and the verification group was 12.9 and 12.2 months, respectively. Multivariate logistic regression analysis after adjusting for sex and age indicated that First-UDCA treatment [odds ratio (OR)=2.543, 95% confidence interval (CI): 1.234-5.240, P=0.011], baseline alanine aminotransferase level (OR=1.265, 95% CI: 1.089-1.471, P=0.002), and baseline total bilirubin level (OR=0.571, 95% CI: 0.420-0.776, P<0.001) were independent factors that influenced the biochemical response in PBC patients after 1 year of UDCA treatment. Therefore, the resulting biochemical response prediction score model represented the sum of the points corresponding to these three variables. The area under the receiver operating characteristic curve of the score model in the derivation group and the verification group was 0.763 (95% CI: 0.701-0.817, P<0.001) and 0.798 (95% CI: 0.681-0.887, P<0.001), respectively. Conclusion We developed and verified an easy-to-use scoring model for the first time, which showed excellent predictive value for the biochemical response in PBC patients.
引用
收藏
页码:1352 / 1360
页数:9
相关论文
共 50 条
  • [41] Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
    Yang, Chunmei
    Guo, Guanya
    Li, Bo
    Zheng, Linhua
    Sun, Ruiqing
    Wang, Xiufang
    Deng, Juan
    Jia, Gui
    Zhou, Xia
    Cui, Lina
    Guo, Changcun
    Zhou, Xinmin
    Leung, Patrick S. C.
    Gershwin, M. Eric
    Shang, Yulong
    Han, Ying
    [J]. HEPATOLOGY INTERNATIONAL, 2023, 17 (01) : 237 - 248
  • [42] Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China
    Chen, Sha
    Duan, Weijia
    Li, Min
    Li, Shuxiang
    Lv, Tingting
    Tian, Qiuju
    Wang, Qianyi
    Wu, Xiaoning
    Zhao, Xinyan
    Wang, Xiaoming
    Wang, Yu
    Kong, Yuanyuan
    Ma, Hong
    Ou, Xiaojuan
    You, Hong
    Jia, Jidong
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (07) : 1236 - 1241
  • [43] Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid.
    Lee Y.M.
    Kaplan M.M.
    [J]. Current Gastroenterology Reports, 1999, 1 (1) : 38 - 41
  • [44] Alteration of Gut Microbiota in Primary Biliary Cholangitis Patients with Non-Response to Ursodeoxycholic Acid
    Lin, Qiu-Xiang
    Lin, Fei
    Gan, Qiao-Rong
    Wang, Xue-Wen
    Huang, Zu-Xiong
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2022, 36 (04) : 1137 - 1145
  • [45] Machine learning prediction model for treatment responders in patients with primary biliary cholangitis
    Kimura, Naruhiro
    Takahashi, Kazuya
    Setsu, Toru
    Goto, Shu
    Miida, Suguru
    Takeda, Nobutaka
    Kojima, Yuichi
    Arao, Yoshihisa
    Hayashi, Kazunao
    Sakai, Norihiro
    Watanabe, Yusuke
    Abe, Hiroyuki
    Kamimura, Hiroteru
    Sakamaki, Akira
    Yokoo, Takeshi
    Kamimura, Kenya
    Tsuchiya, Atsunori
    Terai, Shuji
    [J]. JGH OPEN, 2023, 7 (06): : 431 - 438
  • [46] Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis A meta-analysis
    Wang, Zi-Long
    Song, Kai-Min
    Jin, Rui
    Xie, Yan-Di
    Wang, Yu-Qiong
    Liu, Zhi-Cheng
    Feng, Bo
    [J]. MEDICINE, 2022, 101 (09) : E28987
  • [47] Secondary Treatment of Primary Biliary Cholangitis: Early Prediction of Inadequate Response to Ursodeoxycholic Acid in Patients with PBC
    Liu, Benjamin D.
    Qureshi, Kamran
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 346 - 348
  • [48] Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia
    AlWabel, Ahmed
    Peedikayil, Musthafa
    AlNasser, Sulaiman
    AlHusaini, Khalid
    AlHekail, Othman
    Alqahtani, Saleh
    AlTraif, Ibrahim
    AlAshgar, Hamad
    [J]. SAUDI JOURNAL OF GASTROENTEROLOGY, 2023, 29 (02) : 135 - 140
  • [49] Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
    Alomari, Mohammad
    Covut, Fahrettin
    Al Momani, Laith
    Chadalavada, Pravallika
    Hitawala, Asif
    Young, Mark F.
    Romero-Marrero, Carlos
    [J]. JGH OPEN, 2020, 4 (02): : 132 - 139
  • [50] An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance
    Sahu, Rakesh
    Mishra, Rakhi
    Majee, Chandana
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (10) : 985 - 998